Published in Clin Infect Dis on April 15, 2008
CpG DNA as a vaccine adjuvant. Expert Rev Vaccines (2011) 2.17
TLR-based immune adjuvants. Vaccine (2010) 2.10
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS (2010) 1.80
Accelerating next-generation vaccine development for global disease prevention. Science (2013) 1.73
Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A (2014) 1.36
Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PLoS One (2011) 1.09
Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery. Proc Natl Acad Sci U S A (2012) 1.08
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine (2014) 1.07
Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS (2011) 1.02
Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol (2014) 0.97
Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis (2012) 0.95
Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review. World J Gastroenterol (2014) 0.93
Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis (2014) 0.91
Clear and independent associations of several HLA-DRB1 alleles with differential antibody responses to hepatitis B vaccination in youth. Hum Genet (2009) 0.87
Distinct TLR-mediated cytokine production and immunoglobulin secretion in human newborn naïve B cells. Innate Immun (2016) 0.82
Rapid loss of vaccine-acquired hepatitis B surface antibody after three doses of hepatitis B vaccination in HIV-infected persons. Int J STD AIDS (2013) 0.79
CpG ODN and ISCOMATRIX adjuvant: a synergistic adjuvant combination inducing strong T-Cell IFN-γ responses. Biomed Res Int (2013) 0.79
Hepatitis B vaccination for reducing morbidity and mortality in persons with HIV infection. Cochrane Database Syst Rev (2014) 0.78
Vaccination in HIV-infected adults. AIDS Patient Care STDS (2014) 0.77
Persistence of Protective Hepatitis B Surface Antibody Titers after Successful Double-Dose Hepatitis B Virus Rescue Vaccination in HIV-Infected Patients. Gut Liver (2012) 0.76
Immunogenicity of a peptide-based anti-IgE conjugate vaccine in non-human primates. Immun Inflamm Dis (2016) 0.75
Phase 1 testing of detoxified LPS/group B meningococcal outer membrane protein vaccine with and without synthetic CPG 7909 adjuvant for the prevention and treatment of sepsis. Vaccine (2015) 0.75
HIV Envelope Trimer Specific Immune Response Is Influenced by Different Adjuvant Formulations and Heterologous Prime-Boost. PLoS One (2016) 0.75
Serological response to trivalent inactivated influenza vaccine in HIV-infected adults in Singapore. Hum Vaccin Immunother (2017) 0.75
Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on the Gastrointestinal (GI) Tract. Front Genet (2017) 0.75
Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med (1993) 8.49
Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis (1991) 7.05
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIV: how much really is known? Sex Transm Dis (2001) 4.73
Human immunodeficiency virus infection among men with sexually transmitted diseases. Experience from a center in Africa. N Engl J Med (1988) 4.55
The interaction of HIV infection and other sexually transmitted diseases: an opportunity for intervention. AIDS (1989) 3.48
Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 2.82
Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol (2000) 2.73
Prevention of transmission of human immunodeficiency virus in Africa: effectiveness of condom promotion and health education among prostitutes. Lancet (1988) 2.33
Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med (1997) 2.27
Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area. Int J Tuberc Lung Dis (2009) 2.22
A model to rule out smear-negative tuberculosis among symptomatic HIV patients using C-reactive protein. Int J Tuberc Lung Dis (2012) 2.13
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol (2004) 1.98
Heterosexual transmission of HIV. AIDS (1987) 1.84
Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol (2001) 1.84
Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci U S A (1998) 1.81
CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine (2000) 1.80
Five-drug therapy for advanced breast cancer: a phase I study. Cancer Chemother Rep (1971) 1.77
A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol (1995) 1.76
Breast cancer incidence highest in the range of one species of house mouse, Mus domesticus. Br J Cancer (2000) 1.73
Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis (1994) 1.71
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine (2004) 1.71
CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A (1998) 1.70
Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol (2001) 1.65
Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther (2000) 1.62
DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans. Proc Natl Acad Sci U S A (1995) 1.60
A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis (2003) 1.59
Development of Kaposi's sarcoma despite sustained suppression of HIV plasma viremia. J Acquir Immune Defic Syndr (1999) 1.59
Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS (1999) 1.58
The role of CpG dinucleotides in DNA vaccines. Trends Microbiol (1998) 1.57
Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun (2001) 1.55
Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology (2000) 1.49
CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol (1998) 1.48
Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med (1978) 1.48
Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions. Clin Infect Dis (2001) 1.44
The use of ozone-treated blood in the therapy of HIV infection and immune disease: a pilot study of safety and efficacy. AIDS (1991) 1.40
The utility of verbal autopsies for identifying HIV-1-related deaths in Haitian children. AIDS (1993) 1.34
Interleukin-7 receptor expression on CD8(+) T cells is reduced in HIV infection and partially restored with effective antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.33
Intrahepatic arterial infusion with 5-fluorouracil. Cancer (1971) 1.27
Chemotherapy of large bowel cancer. Cancer (1982) 1.25
Tuberculosis at Edendale Hospital in Pietermaritzburg, Kwazulu Natal, South Africa. Int J Tuberc Lung Dis (2004) 1.24
Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med (2012) 1.23
Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med (1999) 1.22
Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine (2000) 1.22
Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine (1999) 1.20
Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Defic Syndr (1999) 1.19
Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ (1999) 1.19
CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol (1999) 1.19
Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis (1998) 1.18
Standardization of an enzyme immunoassay for human antibody to Haemophilus ducreyi. J Clin Microbiol (1992) 1.17
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer (1975) 1.16
Effect of antiretroviral therapy and viral load on the perceived risk of HIV transmission and the need for safer sexual practices. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.14
Trophic effect of ciliary neurotrophic factor on denervated skeletal muscle. Cell (1994) 1.14
Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya. Antimicrob Agents Chemother (1989) 1.13
A randomized controlled psycho-education intervention trial: Improving psychological readiness for successful HIV medication adherence and reducing depression before initiating HAART. AIDS Care (2006) 1.11
DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci U S A (1996) 1.11
Comparison of interferon-γ-, interleukin (IL)-17- and IL-22-expressing CD4 T cells, IL-22-expressing granulocytes and proinflammatory cytokines during latent and active tuberculosis infection. Clin Exp Immunol (2012) 1.10
Primary squamous cell carcinoma of the breast: sensitivity to cisplatinum-based chemotherapy. J Surg Oncol (1995) 1.08
Acute phase responses and cytokine secretion in chronic fatigue syndrome. J Clin Immunol (1999) 1.07
Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol (1999) 1.07
Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations. Cancer Treat Rep (1979) 1.07
CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol (2001) 1.06
Human immunodeficiency virus, genital ulcers and the male foreskin: synergism in HIV-1 transmission. Scand J Infect Dis Suppl (1990) 1.04
Differential production of IL-10 by T cells and monocytes of HIV-infected individuals: association of IL-10 production with CD28-mediated immune responsiveness. Clin Exp Immunol (1998) 1.01
The prevalence of Chlamydia trachomatis infection among mothers of children with trachoma. Am J Epidemiol (1990) 1.01
Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther (2001) 1.01
Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression. J Infect Dis (2001) 1.01
Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis (1998) 1.01
Human immunodeficiency virus and the gastrointestinal immune system: does highly active antiretroviral therapy restore gut immunity? Mucosal Immunol (2012) 1.01
Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. Br J Clin Pharmacol (2000) 0.99
The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine (2001) 0.97
Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol (1976) 0.97
Adriamycin cardiotoxicity in children: case reports, literature review, and risk factors. Cancer (1977) 0.96
CpG DNA as mucosal adjuvant. Vaccine (1999) 0.96
Cloning, overexpression, purification, and immunobiology of an 85-kilodalton outer membrane protein from Haemophilus ducreyi. Infect Immun (2001) 0.95
Priming of immune responses to hepatitis B surface antigen in young mice immunized in the presence of maternally derived antibodies. FEMS Immunol Med Microbiol (2001) 0.95
Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J Clin Immunol (1996) 0.95
The role of antitumor antibiotics in current oncologic practice. Cancer Chemother Pharmacol (1978) 0.95
Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS (2000) 0.94
Doxorubicin toxicity. Onycholysis, plantar callus formation, and epidermolysis. JAMA (1975) 0.94
CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine (2000) 0.93
Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine (2001) 0.93
DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Ann N Y Acad Sci (1995) 0.93
A community randomized controlled clinical trial of mixed carotenoids and micronutrient supplementation of patients with acquired immunodeficiency syndrome. Eur J Clin Nutr (2006) 0.93
The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit Rev Immunol (2001) 0.93
Development and psychometric validation of the HIV Treatment Knowledge Scale. AIDS Care (2007) 0.92
A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness. Vaccine (2011) 0.92
Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev (1998) 0.92
Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. Clin Pharmacol Ther (1992) 0.92